Timed pentylenetetrazol infusion test: A comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice

Seizure

Volumn 16, Issue 7, 2007, Pages 636-644

  Mandhane, Sanjay N ^a   Aavula, Keerthikumar ^a   Rajamannar, T ^a  

^a Sun Pharma Advanced Research Centre   (India)

Author keywords

Antiepileptic drugs; Epilepsy; i.v. pentylenetetrazol; Mice

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; DISEASE MODEL; DRUG SCREENING; ELECTRIC SHOCK; LATENT PERIOD; MALE; MOUSE; MYOCLONUS SEIZURE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

ANIMALS; ANTICONVULSANTS; CONVULSANTS; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION, PRECLINICAL; ELECTROSHOCK; EPILEPSY; INDIVIDUALITY; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; PENTYLENETETRAZOLE;

EID: 34548165281     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2007.05.005     Document Type: Article

References (41)

1. Rogawski M.A. Molecular target versus models for new antiepileptic drug discovery. Epilepsy Res 68 (2006) 22-28
2. Kupferberg H. Animal models used in the screening of antiepileptic drugs. Epilepsia 42 Suppl. 4 (2001) 7-12
3. Stables J.P., Bertram E., Dudek F.E., Holmes G., Mathern G., Pitkanen A., et al. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia 44 (2003) 1472-1478
4. White H.S. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 44 Suppl. 7 (2003) 2-8
5. Piredda S.G., Woodhead J.H., and Swinyard E.A. Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. J Pharmacol Exp Ther 232 (1985) 741-745
6. Goodman L.S., Grewal M.S., Brown W.C., and Swinyard E.A. Comparison of maximal seizures evoked by pentylenetetrazol (metrazol) and electroshock in mice and their modification by anticonvulsants. J Pharmacol Exp Ther 108 (1953) 168-176
7. Snead O.C. Pharmacological models of generalized absence seizures in rodents. J Neural Transm Suppl 35 (1992) 7-19
8. Swinyard E.A., Woodhead J.H., White H.S., and Franklin M.R. Experimental selection, quantification and evaluation of anticonvulsants. In: Levy R., Mattson R., Meldrum B., Penry J.K., and Dreifuss F.E. (Eds). Antiepileptic drugs. 3rd ed. (1989), Raven Press, New York 85-102
9. White H.S., Johnson M., Wolf H.H., and Kupferberg H.J. The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital J Neurol Sci 16 (1995) 73-77
10. White H.S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 38 Suppl. (1997) S9-S17
11. Orloff M.J., Williams H.L., and Pfeiffer C.C. Timed intravenous infusion of metrazol and strychnine for testing anticonvulsant drugs. Proc Soc Exp Biol Med 70 (1949) 254-257
12. Nutt D.J., Taylor S.C., and Little H.J. Optimizing the pentetrazol infusion test for seizure threshold measurement. J Pharm Pharmacol 38 (1986) 697-698
13. Pollack G.M., and Shen D.D. A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. J Pharmacol Methods 13 (1985) 135-146
14. Loscher W., Honack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazol seizure models. Epilepsy Res 8 (1991) 171-189
15. Kent A.P., and Webster R.A. The evaluation of different types of anti-convulsant drug activity against leptazol-induced epileptogenic activity in the anesthetized rat. Br J Pharmacol 78 (1983) 553-559
16. Loscher W., and Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2 (1988) 145-181
17. Swinyard E.A., Brown W.C., and Goodman L.S. Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106 (1952) 319-330
18. Schmidt D., and Rogawski M.A. New strategies for the identification of drugs to prevent the development or progression of epilepsy. Epilepsy Res 50 (2002) 71-78
19. White H.S. Chemoconvulsants. In: Peterson S.L., and Albertson T.E. (Eds). Neuropharmacology methods in epilepsy research (1998), CRC, Boca Raton 24-40
20. Yonekawa W.D., Kupferberg H.J., and Woodbury D.M. Relationship between pentylenetetrazol-induced seizures and brain pentylenetetrazol levels in mice. J Pharmacol Exp Ther 214 (1980) 589-593
21. Ramzan I.M., and Levy G. Kinetics of drug action in disease states. XIV. Effect of infusion rate on pentylenetetrazol concentrations in serum, brain and cerebrospinal fluid of rats at onset of convulsions. J Pharmacol Exp Ther 234 (1985) 624-628
22. Ramanjaneyulu R., and Ticku M.K. Interactions of pentamethylenetetrazole and tetrazole analogues with the picrotoxinin site of the benzodiazepine-GABA receptor-ionophore complex. Eur J Pharmacol 98 (1984) 337-345
23. A) receptors: mechanism and site of action. J Pharmacol Exp Ther 298 (2001) 986-995
24. A receptor mRNA levels and GABA stimulation of benzodiazepine binding with no effect on benzodiazepine binding site density. J Pharmacol Exp Ther 289 (1999) 1626-1633
25. Van den Berg R.J., Kok P., and Voskuyl R.A. Valproate and sodium currents in cultured hippocampal neurons. Exp Brain Res 93 (1993) 279-287
26. Kelly K.M., Gross R.A., and Macdonald R.L. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett 116 (1990) 233-238
27. Rogawski M.A., and Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42 (1990) 223-286
28. Czapinski P., Blaszczyk B., and Czuczwar S.J. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 5 (2005) 3-14
29. Wellington K., and Goa K.L. Oxcarbazepine. An update of its efficacy in the management of epilepsy. CNS Drugs 15 (2001) 137-163
30. Bazil C.W., and Pedley T.A. Advances in the medical treatment of epilepsy. Annu Rev Med 49 (1998) 135-162
31. Loscher W., Honack D., and Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 284 (1998) 474-479
32. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101 (2004) 9861-9866
33. Loscher W., Honack D., and Bloms-Funke P. The novel antiepileptic drug (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res 735 (1996) 208-216
34. Sato M., Racine R.J., and McIntyre D.C. Kindling: basic mechanisms and clinical validity. Electroencephalogr Clin Neurophysiol 76 (1990) 459-472
35. Silver J.M., Shin C., and Mcnamara J.O. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann Neurol 29 (1991) 356-363
36. Keogh B.P., Cordes D., Stanberry L., Figler B.D., Robbins C.A., Tempel B.L., et al. BOLD-fMRI of PTZ-induced seizures in rats. Epilepsy Res 66 (2005) 75-90
37. Miller J.W., McKeon A.C., and Ferrendelli J.A. Functional anatomy of pentylenetetrazol and electroshock seizures in the rat brain stem. Ann Neurol 22 (1987) 615-621
38. Borowicz K.K., Luszczki J.J., Duda A.M., and Czuczwar S.J. Effect of topiramate on the anticonvulsant activity of conventional antiepileptic drugs in two models of experimental epilepsy. Epilepsia 44 (2003) 640-646
39. Gee N.S., Brown J.P., Dissanayake V.U., Offord J., Thurlow R., and Woodruff G.N. The novel anticonvulsant drug, gabapentin (neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 271 (1996) 5768-5776
40. Errington A.C., Stohr T., and Lees G. Voltage gated ion channels: targets for anticonvulsant drugs. Curr Top Med Chem 5 (2005) 15-30
41. Fariello R.G., McArthur R.A., Bonsignori A., Cervini M.A., Maj R., Marrari P., et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther 285 (1998) 397-403